share_log

Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target

Moomoo 24/7 ·  Mar 25 11:54

Truist Securities analyst Robyn Karnauskas reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment